← Leaderboards
Michael R Sierks
University Of Maryland Balt Co Campus
$4,430,222
Attributed
$4,618,403
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $431.8K · FY2008–22$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,618,403 · 7
By mechanism
R01$2,615,372 · 2
R21$2,003,031 · 5
Top collaborators
- Anne Messer2 shared
Others in their field
Top investigators on “Alpha Synuclein”
- David A Bennett · Rush University Medical Center$22,290,036
- Joel Synes Perlmutter · Washington University$19,346,398
- John Q. Trojanowski · University Of Pennsylvania$18,630,803
- Robert H Mach · Wake Forest University$18,190,792
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$17,941,681
- Jie Shen · Brigham And Women'S Hospital$16,692,040
Research focus
Alpha SynucleinAlzheimer&AposImmunoglobulin FragmentsVariantNeurodegenerative DisordersS DiseaseAmyloid Beta-ProteinProteinsBaseReagentMorphologyParkinson DiseaseTau ProteinsDisease ProgressionDirect ApplicationAntibodiesDiagnosisGenerationsIn VivoAmyotrophic Lateral SclerosisBrainNeuronsNanobodiesSampling
Grant awards (19)
Purification and Characterization of a toxic AD associated intracellularly generated amyloid beta fragment$431,750
R21 · FY2022 · AG · contact PI
Protein variants as blood based biomarkers for diagnosing and staging AD$349,601
R01 · FY2020 · AG · contact PI
Protein variants as blood based biomarkers for diagnosing and staging AD$349,601
R01 · FY2019 · AG · contact PI
Protein variants as blood based biomarkers for diagnosing and staging AD$349,601
R01 · FY2018 · AG · contact PI
Protein variants as blood based biomarkers for diagnosing and staging AD$349,601
R01 · FY2017 · AG · contact PI
Protein variants as blood based biomarkers for diagnosing and staging AD$363,437
R01 · FY2016 · AG · contact PI
Nanobodies selective for oligomeric Tau species isolated from AD brain$193,125
R21 · FY2014 · AG · contact PI
Nanobodies selective for oligomeric Tau species isolated from AD brain$238,339
R21 · FY2013 · AG · contact PI
Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species$182,707
R21 · FY2013 · AG · contact PI
Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species$245,484
R21 · FY2012 · AG · contact PI
Intracellular tools to study specific misfolded protein variants in human disease$153,411
R21 · FY2012 · AG · contact PI
Intracellular tools to study specific misfolded protein variants in human disease$181,853
R21 · FY2011 · AG · contact PI
Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools$199,968
R21 · FY2009 · NS · contact PI
Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools$176,394
R21 · FY2008 · NS · contact PI
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES$255,980
R01 · FY2003 · AG
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES$43,857
R01 · FY2003 · AG
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES$187,500
R01 · FY2002 · AG
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES$187,500
R01 · FY2001 · AG
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES$178,694
R01 · FY2000 · AG